Certara
CERT Small CapHealthcare · Health Information Services
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Certara en bref
Certara (CERT) is currently trading at 7,02 € with a market capitalization of 1,1 Md €. The 52-week range spans from 3,86 € to 12,03 €; the current price is 41.6% below the yearly high. Year-over-year revenue growth stands at +0.9%.
💰 Dividende
Certara currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
10 analystes évaluent Certara (CERT) au consensus : Acheter. L'objectif de cours moyen est de 6,53 €, soit un potentiel de -7.04% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 5,20 € à 8,67 €.
Certara : la thèse d'investissement en détail
Certara (CERT) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 61.59%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Revenue growth has slowed to just 0.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 29.61% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 61.59% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 29.95)
- Free cash flow positif
- –Actuellement non rentable
- –Positions vendeuses élevées (29.61%)
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (29.61%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Certara?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news